BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//European Society of Pathology - ECPv6.18.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:European Society of Pathology
X-ORIGINAL-URL:https://www.esp-pathology.org
X-WR-CALDESC:Events for European Society of Pathology
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260622
DTEND;VALUE=DATE:20260625
DTSTAMP:20260629T123939Z
CREATED:20260213T134116Z
LAST-MODIFIED:20260629T123939Z
UID:10000031-1782086400-1782345599@www.esp-pathology.org
SUMMARY:EScoP Course on Infectious Diseases
DESCRIPTION:ESP webinar on Solid Tumours (Agnostic) Biomarker Testing				\n				\n				\n				\n					18 November 2026 | 15:00 - 16:00 CET				\n				\n					\n				\n		\n					\n					\n				\n					\n				\n				\n		\n					\n				\n				\n							\n			\n					\n					\n								\n					\n				Overview			\n		\n				\n					\n								\n					\n				Faculty			\n		\n				\n					\n								\n					\n				Programme			\n		\n				\n					\n								\n					\n				Registration			\n		\n				\n					\n								\n					\n				Attendance Certificate			\n		\n					\n			\n				\n		\n					\n				\n				\n					Webinar Overview				\n				\n				\n				\n									The development of novel treatment options has allowed the design of potential agnostic therapeutic strategies for solid tumours. Those are based on detecting several biomarkers like HER2 overexpression\, MMR proteins\, NTRK Gene Fusions\, BRAF V600E mutations and more. The novel approach has application to cancers like breast\, lung\, and more. Recently\, there was a positive view from EMA/ CHMP\, and in specific for HER2-positive (immunohistochemistry [IHC] 3+)\, signalling the importance of updating the medical community on this subject. This webinar will present the role of pathology in tumour agnostic testing\, the potential pitfalls\, and how to use the newest scientific developments in the field for optimal cancer patient management. The organisation of the webinar is supported by Daiichi Sankyo Europe GmbH. 								\n				\n					\n				\n		\n				\n				\n		\n					\n		\n				\n				\n					Faculty				\n				\n				\n				\n									Speakers:    								\n				\n				\n					\n				\n		\n		\n					\n				\n				\n					Webinar Programme				\n				\n				\n				\n									15:00 – 16:00 CET								\n				\n					\n				\n				\n		\n		\n					\n				\n				\n					Registration				\n				\n				\n				\n									The webinar is offered free of charge and will be conducted via ZOOM. Please click on the below button to register.  								\n				\n				\n				\n									\n					\n						\n									Register now!\n					\n					\n				\n								\n				\n					\n				\n				\n		\n					\n		\n				\n				\n					Certificate of Attendance				\n				\n				\n				\n									ESP members will receive a personalised certificate for their participation. The webinar will be recorded and made available via the ESP educational platform.
URL:https://www.esp-pathology.org/event/infectious-diseases/
END:VEVENT
END:VCALENDAR